Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab with Lenalidomide/Dexamethasone in Newly Diagnosed Multiple Myeloma
NCT03283046Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2017
- Primary completion
- Oct 2020
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of nivolumab in multiple myeloma (MM), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum Tolerated Dose at 28 days and Adverse Events. Planned start Oct 2017; status: withdrawn.
02
Drugs
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03283046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03283046.